Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Intranasal Desmopressin Loses Indication for Primary Nocturnal Enuresis in Canada - (DGNews)
    TopAbstracts in Diabetes 07/15/2008 - (DGNews)
    Many Hispanics With Diabetes Not Receiving Eye Exams, Unaware of Retinopathy - (DGNews)
    Fetuin-A and incident diabetes mellitus in older persons - (JAMA)
    TopAbstracts in Diabetes 07/08/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Diabetes
  • Beyond Glycemic Control: Managing Obesity and Cardiovascular Disease Risk for Patients With Type 2 Diabetes in the Primary Care Setting
  • Managing Atherogenic Dyslipidemia and the Microvascular Complications of Insulin Resistance with Fenofibrate
    Diabetic Peripheral Neuropathies

    Webcasts/CME archive

     Recent cases - Diabetes
      Somatostatinoma: A Rare Cause of Diabetic Ketosis
      New Onset Diabetes Complicated by Haemolysis and Rhabdomyolysis: A Case Report and Review of the Literature
      Diabetic Control and Atypical Antipsychotics: A Case Report
      Treatment with Pioglitazone Induced Significant, Reversible Mitral Regurgitation
      An Elderly Patient with Sarcoidosis Manifesting Panhypopituitarism with Central Diabetes Insipidus

      Cases archive
        




      my personal edition > diabetes > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Morning Insulin Glargine Decreases Risk of Nocturnal Hypoglycaemia in Type 2 Diabetics, Compared to Night-Time Insulin

      A DGReview of :"Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes: A Randomized, Controlled Trial"
      Annals of Internal Medicine

      07/04/2003
      By Emma Hitt, PhD


      Morning insulin glargine appears to lower the risk of nocturnal hypoglycaemia in type 2 diabetics who take the sulfonylurea drug glimepiride, compared with bedtime insulin glargine or bedtime NPH insulin.

      Therapy with oral antidiabetic drugs and bedtime neutral protamine Hagedorn (NPH) insulin is as effective as other, more complex insulin regimens and is associated with less weight gain. However, NPH insulin exhibits a peak of action 4 to 6 hours after injection and is associated with an increased risk of nocturnal hypoglycaemia.

      By comparison, insulin glargine, a newer human insulin analogue, exhibits a 24-hour action profile and may be more effective in achieving glycaemic control compared to NPH when combined with oral antidiabetic drugs.

      In their study, Andreas Fritsche, MD, with the Eberhard-Karls-Universitat, Tubingen, Germany, and colleagues conducted an open-label, randomised, controlled trial of 695 patients with type 2 diabetes whose diabetes was poorly controlled with oral antidiabetic drugs alone. Patients were randomised to treatment with morning insulin glargine, bedtime NPH insulin, or bedtime insulin glargine for 24 weeks in addition to 3 mg of glimepiride.

      Haemoglobin A(1c) improvement was more pronounced with morning insulin glargine than with NPH insulin (p = 0.001) or bedtime insulin glargine (p = 0.008). Haemoglobin A(1c) levels improved by -1.24% with morning insulin glargine, -0.96% with bedtime insulin glargine, and by -0.84% with bedtime NPH insulin.

      Improvement in baseline to end-point fasting blood glucose levels was similar in all three groups, the researchers found. However, patients receiving morning insulin glargine experienced the least nocturnal hypoglycaemia (17% with morning insulin glargine versus 23% with bedtime insulin glargine and 38% with NPH insulin, p < 0.001).

      "Insulin glargine injected in the morning resulted in better glycaemic control than did bedtime NPH insulin, " the researchers conclude. "This can be explained by the longer action profile of insulin glargine and, therefore, better 24-hour glycaemic control."

      However, the finding that insulin glargine results in better glycaemic control only when given in the morning was "unexpected and is not easy to explain," they point out. They speculate that the reason for the better glycaemic control with morning insulin glargine is that the glucose-lowering effect of insulin glargine given in the morning together with glimepiride might be higher during the first 12 hours after insulin glargine injection.
      Ann Intern Med 2003;138:12:952-959. "Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes: A Randomized, Controlled Trial"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send